Zervixkarzinome in Mecklenburg-Vorpommern

Marquardt, Katrin; Stubbe, Muriel; Broschewitz, U

doi:10.1007/s00292-015-0120-1

Cited by 13 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cancer stage at diagnosis is a critical determinant of cancer outcomes and is directly associated with survival in cancer patients 10 . Previous studies showed that women rarely or never screened were more likely to be diagnosed at late stage than women undergoing routine screenings 11–15 . Our study showed that patients were more likely to be diagnosed at an early stage with more frequent screening.…”

Section: Discussionmentioning

confidence: 98%

The effect of Pap smear screening on cervical cancer stage among southern Thai women

Niu

Virani

Bilheem

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Our study aimed to investigate the effect of Pap smear screening on stage at diagnosis of cervical cancer in a heterogeneous population of Thai women. Data was merged from the population-based cancer registry and screening registry based on unique identification numbers from 2006 to 2014. Patients being screened had lower odds to be diagnosed at late stage. After adjustment, married women had reduced risk of late stage cancer compared to single women. Muslim women had almost twice the risk of being diagnosed late stage compared to Buddhist women. The odds of being diagnosed at late stage decreased with increased number of screening. The probability of being diagnosed at late stage increased rapidly among females aged 40 to 55 years. Pap smear screening is a protective factor in diagnosis of late stage cervical cancer. Patients were more likely to be diagnosed at early stage with more frequent screening. For future screening programs, it will be beneficial to shorten screening intervals and take more concern for vulnerable population: women aged between 40 and 55 years, and women who are single or Muslim.

show abstract

Section: Discussionmentioning

confidence: 98%

The effect of Pap smear screening on cervical cancer stage among southern Thai women

Niu

Virani

Bilheem

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In Germany, a case study conducted in Mecklenburg-Western Pomerania retrospectively investigated CCS participation preceding a cervical cancer diagnosis. Fifty-eight per cent of women with cervical cancer had no Pap smear taken in the five years prior to diagnosis, whilst the remaining 42% had at least one Pap smear recorded in this period [9]. These findings were based on cytological laboratories records reported to the Quality Assurance Commission of the Medical Association in Mecklenburg-Western Pomerania.…”

Section: Plos Onementioning

confidence: 99%

“…The estimated triennial participation rate ranges from 75% to 85% [6][7][8]. Data on the association between CCS participation and cervical cancer in Germany are limited to case series and reports but indicate that participation in CCS has been low among women who developed this malignancy [9]. Therefore, the present study aimed to investigate the impact of opportunistic CCS on cervical cancer, adjusting for known and potential risk factors including socio-demographic characteristics, smoking, oral contraceptive (OC) use, parity, body mass index (BMI), and physical activity.…”

Section: Introductionmentioning

confidence: 99%

Impact of opportunistic screening on squamous cell and adenocarcinoma of the cervix in Germany: A population-based case-control study

et al. 2021

View full text Add to dashboard Cite

Background We investigated the uptake of opportunistic cervical cancer screening (CCS) and other risk factors and their association with cervical cancer in Germany in a case-control study. Methods and findings We recruited incident cases of cervical cancer (ICD-10 C53) diagnosed between 2012 and 2016 and matched with three population-based controls, based on age and region of residence. Cases and controls reported their CCS participation during the past ten years (frequent: every three years; no or infrequent: less than every three years) and other relevant variables. We fitted conditional logistic regression models, reporting odds ratios (OR) and 95% confidence intervals (95% CI). We report overall and stratified analyses by histologic group (squamous cell–SCC, and adenocarcinoma–AC), T category (T1 and T2+), and age (<50 and ≥50 years). We analysed 217 cases and 652 matched controls. 53.0% of cases and 85.7% of controls attended CCS frequently. In the overall adjusted model, no or infrequent participation in CCS (OR 5.63; 95% CI 3.51 to 9.04), having had more than one sexual partner (OR 2.86; 95%CI 1.50 to 5.45) and obesity (OR 1.69; 95% CI 1.01 to 2.83) were associated with cervical cancer. Twelve years of schooling (OR 0.37; 95% CI 0.23 to 0.60) and a net monthly income of €3000 or more (OR 0.50; 95% CI 0.30 to 0.82) were protective factors. In the stratified analyses, no or infrequent participation was associated with T1 (OR 4.37; 95% CI 2.48 to 7.71), T2+ (OR 10.67; 95% CI 3.83 to 29.74), SCC (OR 6.88; 95% CI 4.08 to 11.59) and AC (OR 3.95; 95% CI 1.47 to 10.63). Conclusion Although women who frequently attended CCS were less likely to develop cervical cancer, especially larger tumours, the high proportion of cases who had been frequently screened prior to diagnosis underscores the need to investigate the quality of cytology and treatment of precancerous lesions in Germany.

show abstract

“…Mit diesem Konzept und den Abklärungsmodalitäten bei auffälliger Zytologie konnte die Inzidenz des Zervixkarzinoms um mehr als 70 % gesenkt werden [10,26]. Bei der Restinzidenz des Zervixkarzinoms unter Screening-Teilnehmerinnen handelt es sich überwiegend um prognostisch günstige Karzinome [4,19].…”

Section: Statistische Auswertungunclassified

Risikobewertung von Zytologiebefunden im Zervixkarzinom-Screening

Marquardt¹,

Ziemke²,

Neumann

et al. 2019

Gynäkologe

View full text Add to dashboard Cite

Risikobewertung von Zytologiebefunden im Zervixkarzinom-Screening Mit der ab 2020 gültigen Krebsfrüherkennungsrichtlinie gelten im deutschen Zervixkarzinom-Screening erstmals Algorithmen zur Abklärung auffälliger Befunde. Bisher besteht lediglich Konsens hinsichtlich der Therapiebedürftigkeit einer CIN3 (zervikale intraepitheliale Neoplasie). Das Management bei Zellbildern der Gruppe IIID ebenso wie bei den Gruppen II und III ist durchaus unterschiedlich mit Kontrollzytologie, HPV(humane Papillomviren)-Test, Immunzytochemie und Kolposkopie. Für ein risikoadaptiertes Procedere mit Vermeidung von Überdiagnostik bei Gewährleistung der nötigen Sicherheit für die Patientinnen sollte das Risiko der einzelnen zytologischen Befunde bekannt sein.

show abstract

Zervixkarzinome in Mecklenburg-Vorpommern

Abstract: Most cervical cancers and the advanced stages were found in women who did not participate in the screening program.

Cited by 13 publications

References 9 publications

The effect of Pap smear screening on cervical cancer stage among southern Thai women

The effect of Pap smear screening on cervical cancer stage among southern Thai women

Impact of opportunistic screening on squamous cell and adenocarcinoma of the cervix in Germany: A population-based case-control study

Risikobewertung von Zytologiebefunden im Zervixkarzinom-Screening

Contact Info

Product

Resources

About